Patents by Inventor Gil Yong Ji

Gil Yong Ji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody binding specifically to CD40 and use thereof
    Patent number: 11905331
    Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 20, 2024
    Assignee: KUMHO HT, INC.
    Inventors: Gil Yong Ji, Kwon Pyo Hong, Eui Sup Lee, Yoo Ri Moon, Sangsoon Yoon
  • ANTIBODY BINDING SPECIFICALLY TO CD40 AND USE THEREOF
    Publication number: 20230192875
    Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.
    Type: Application
    Filed: November 10, 2017
    Publication date: June 22, 2023
    Inventors: Gil Yong JI, Kwon Pyo HONG, Eui Sup LEE, Yoo Ri MOON, Sangsoon YOON
  • USE FOR PREVENTING AND TREATING MYELOID-DERIVED SUPPRESSOR CELL-RELATED DISEASES
    Publication number: 20220119518
    Abstract: The present invention relates to an antibody or an antigen-binding fragment thereof specifically binding to CD66c which is expressed in myeloid-derived suppressor cell (MDSC) and a use thereof, and specifically to an antibody or an antigen-binding fragment thereof specifically binding to CD66c, a pharmaceutical composition or a diagnosing composition including the same. The anti-CD66c antibody of the present invention can be used usefully for the treatment of various diseases by targeting MDSC which can induce the immunosuppression.
    Type: Application
    Filed: May 14, 2019
    Publication date: April 21, 2022
    Inventors: Soseul KIM, Jeong Won HONG, Gil Yong JI, Sangsoon YOON, Hyung-Geun SONG
  • Antibody binding specifically to CD66c and use thereof
    Patent number: 11220543
    Abstract: The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: January 11, 2022
    Assignee: DINONA
    Inventors: Sangsoon Yoon, Kwon Pyo Hong, Soseul Kim, Gil Yong Ji, Young Hoon Lim
  • Antibody binding to carbonic anhydrase and use thereof
    Patent number: 10975160
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 13, 2021
    Assignee: APROGEN KIC INC.
    Inventors: Yoo Ri Moon, Gil Yong Ji
  • Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
    Patent number: 10472418
    Abstract: A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: November 12, 2019
    Assignee: Dinona
    Inventors: Kwon Pyo Hong, Mi Hyang Shin, Sangsoon Yoon, Gil Yong Ji, Yoo Ri Moon
  • ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
    Publication number: 20190263905
    Abstract: The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.
    Type: Application
    Filed: November 14, 2017
    Publication date: August 29, 2019
    Inventors: Sangsoon YOON, Kwon Pyo HONG, Soseul KIM, Gil Yong JI, Young Hoon LIM
  • ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOF
    Publication number: 20190153116
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Inventors: Yoo Ri MOON, Gil Yong Ji
  • Antibody binding to carbonic anhydrase and use thereof
    Patent number: 10246517
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: April 2, 2019
    Assignee: APROGEN KIC INC.
    Inventors: Yoo Ri Moon, Gil Yong Ji
  • ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOF
    Publication number: 20170342161
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Application
    Filed: November 7, 2016
    Publication date: November 30, 2017
    Inventors: Yoo Ri MOON, Gil Yong JI
  • COMPOSITION FOR PREVENTING OR TREATING LUNG CANCER COMPRISING ANTIBODY AGAINST CD66C AND CHEMOTHERAPEUTIC AGENT
    Publication number: 20170267757
    Abstract: A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 21, 2017
    Inventors: Kwon Pyo HONG, Mi Hyang Shin, Sangsoon Yoon, Gil Yong Ji, Yoo Ri Moon